AR041205A1 - Derivados de 1,3,8- triazaspiro (4,5) decan-4 - ona hidroxi alquil sustituidos utiles para el tratamiento de trastornos mediados por el receptor orl-1 - Google Patents

Derivados de 1,3,8- triazaspiro (4,5) decan-4 - ona hidroxi alquil sustituidos utiles para el tratamiento de trastornos mediados por el receptor orl-1

Info

Publication number
AR041205A1
AR041205A1 ARP030103248A ARP030103248A AR041205A1 AR 041205 A1 AR041205 A1 AR 041205A1 AR P030103248 A ARP030103248 A AR P030103248A AR P030103248 A ARP030103248 A AR P030103248A AR 041205 A1 AR041205 A1 AR 041205A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heteroaryl
alkoxy
hydroxy
Prior art date
Application number
ARP030103248A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041205(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR041205A1 publication Critical patent/AR041205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP030103248A 2002-09-09 2003-09-08 Derivados de 1,3,8- triazaspiro (4,5) decan-4 - ona hidroxi alquil sustituidos utiles para el tratamiento de trastornos mediados por el receptor orl-1 AR041205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40913402P 2002-09-09 2002-09-09

Publications (1)

Publication Number Publication Date
AR041205A1 true AR041205A1 (es) 2005-05-11

Family

ID=31978719

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103248A AR041205A1 (es) 2002-09-09 2003-09-08 Derivados de 1,3,8- triazaspiro (4,5) decan-4 - ona hidroxi alquil sustituidos utiles para el tratamiento de trastornos mediados por el receptor orl-1

Country Status (19)

Country Link
US (3) US7081463B2 (https=)
EP (1) EP1601674B1 (https=)
JP (1) JP4712384B2 (https=)
KR (1) KR20050043935A (https=)
CN (1) CN100402529C (https=)
AR (1) AR041205A1 (https=)
AU (1) AU2003268512A1 (https=)
BR (1) BR0306309A (https=)
CA (1) CA2498275C (https=)
CL (1) CL2003001814A1 (https=)
EA (1) EA009369B1 (https=)
MX (1) MXPA05002622A (https=)
NO (1) NO20051743L (https=)
NZ (1) NZ538307A (https=)
PL (1) PL377047A1 (https=)
RS (1) RS20050208A (https=)
TW (1) TWI296627B (https=)
WO (1) WO2004022558A2 (https=)
ZA (1) ZA200502836B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538307A (en) 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
US20080287478A1 (en) * 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CN101273046B (zh) 2005-09-28 2011-05-25 弗·哈夫曼-拉罗切有限公司 作为加压素受体拮抗剂的吲哚-3-基-羰基氮杂螺环衍生物
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
KR20090087042A (ko) * 2006-11-28 2009-08-14 얀센 파마슈티카 엔.브이. 알콜 남용, 중독 및 의존증 치료방법
CN103202840B (zh) 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
JP5490677B2 (ja) * 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP3406607A1 (en) 2012-12-21 2018-11-28 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
EP3177288A4 (en) 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102043337B1 (ko) 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
JP7011596B2 (ja) * 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CA3014572C (en) 2016-02-25 2023-10-03 Asceneuron S.A. Acid addition salts of piperazine derivatives
KR20180132629A (ko) 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
MX2020003242A (es) 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2020039029A1 (en) * 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
JP7407171B2 (ja) 2018-08-22 2023-12-28 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677421A (en) * 1900-10-19 1901-07-02 Kate Hatch Mcrae Cake-beater.
US3155699A (en) * 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) * 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) * 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) * 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
JPS57212180A (en) * 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
EP0661972A1 (en) 1991-12-27 1995-07-12 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
ATE191486T1 (de) 1993-09-09 2000-04-15 Scios Inc Pseudo-oder nicht peptidartige bradykinin rezeptor antagoniste
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
ES2170446T3 (es) * 1997-12-05 2002-08-01 Hoffmann La Roche Derivados de 1,3,8-triaza-espiro(4,5)decan-4-ona.
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
WO1999059997A1 (en) * 1998-05-18 1999-11-25 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
DE69900220T2 (de) 1998-06-12 2002-05-08 F. Hoffmann-La Roche Ag, Basel Diaza-spiro[3,5]nonan-Derivate
EP1087770A4 (en) * 1998-06-15 2001-11-14 Merck & Co Inc PRENYL PROTEIN TRANSFERASE INHIBITORS
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
ATE289307T1 (de) * 1998-10-23 2005-03-15 Pfizer 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten
AU768708B2 (en) 1998-11-20 2004-01-08 Smithkline Beecham Laboratoires Pharmaceutiques Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
WO2001036418A1 (en) * 1999-11-17 2001-05-25 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
US6686370B2 (en) 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
JP2005231995A (ja) * 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
AU2001262729A1 (en) 2000-06-14 2001-12-24 Banyu Pharmaceutical Co., Ltd 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
CA2443868C (en) 2001-04-10 2011-01-25 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
KR100628292B1 (ko) 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
WO2003010168A1 (fr) 2001-07-23 2003-02-06 Banyu Pharmaceutical Co., Ltd. Derive de 4-oxoimidazolidine-2-spiropiperidine
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
NZ538307A (en) * 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
US20070254903A1 (en) 2003-12-23 2007-11-01 Arena Pharmaceuticals, Inc. Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof
TW200621244A (en) * 2004-08-19 2006-07-01 Vertex Pharma Modulators of muscarinic receptors
AU2005287057A1 (en) 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (spirocyclylamido) aminothiophene compounds as c-Kit proto- oncogene inhibitors
US7655670B2 (en) * 2005-06-02 2010-02-02 Janssen Pharmaceutica N.V. 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
KR20090087042A (ko) 2006-11-28 2009-08-14 얀센 파마슈티카 엔.브이. 알콜 남용, 중독 및 의존증 치료방법
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Also Published As

Publication number Publication date
CN1694883A (zh) 2005-11-09
EP1601674A2 (en) 2005-12-07
EA200500331A1 (ru) 2005-08-25
US20060030577A1 (en) 2006-02-09
RS20050208A (sr) 2007-08-03
US20090124614A1 (en) 2009-05-14
AU2003268512A1 (en) 2004-03-29
US8778956B2 (en) 2014-07-15
JP2006500393A (ja) 2006-01-05
TWI296627B (en) 2008-05-11
JP4712384B2 (ja) 2011-06-29
US7081463B2 (en) 2006-07-25
CN100402529C (zh) 2008-07-16
NZ538307A (en) 2008-04-30
TW200418857A (en) 2004-10-01
US7582649B2 (en) 2009-09-01
CA2498275C (en) 2011-07-12
WO2004022558A2 (en) 2004-03-18
KR20050043935A (ko) 2005-05-11
MXPA05002622A (es) 2005-09-08
US20040142955A1 (en) 2004-07-22
EA009369B1 (ru) 2007-12-28
EP1601674B1 (en) 2012-08-08
NO20051743L (no) 2005-05-18
CA2498275A1 (en) 2004-03-18
ZA200502836B (en) 2006-06-28
BR0306309A (pt) 2004-10-19
PL377047A1 (pl) 2006-01-23
CL2003001814A1 (es) 2005-02-11
WO2004022558A3 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
AR041205A1 (es) Derivados de 1,3,8- triazaspiro (4,5) decan-4 - ona hidroxi alquil sustituidos utiles para el tratamiento de trastornos mediados por el receptor orl-1
AR050966A1 (es) Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)
AR054982A1 (es) Compuestos de piperidinilamino-tieno [2,3-d] pirimidina
AR062640A1 (es) Compuestos de azolcarboxamidas y composiciones herbicidas
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR077462A1 (es) 3-oxo-2,3-dihidro-1h-isoindol-4-carboxamidas
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
AR053739A1 (es) Compuestos espiro condensados como inhibidores de la aldosterona sintasa
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
CO6170406A2 (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR076551A1 (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi
AR060525A1 (es) Piridin [3,4-b] pirazinonas. composiciones farmaceuticas
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR073574A1 (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
AR066293A1 (es) Amidas sustituidas utiles para ser usadas como farmacos
AR068511A1 (es) Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
AR044005A1 (es) Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR042827A1 (es) Compuestos de furano condensados

Legal Events

Date Code Title Description
FB Suspension of granting procedure